Multiple Myeloma

>

Latest News

The safety profile of venetoclax combined with bortezomib and dexamethasone was consistent with previously published results.
Venetoclax Combo Achieves Mixed Results in Relapsed/Refractory Multiple Myeloma

October 17th 2025

Venetoclax with bortezomib and dexamethasone led to a median PFS of 23.4 months compared with 11.4 months with placebo in patients with R/R MM.

Investigators plan to present detailed findings from the MajesTEC-3 study at a future medical conference and share them with regulatory authorities.
Teclistamab/SC Daratumumab Improves Survival in R/R Multiple Myeloma

October 16th 2025

The addition of comprehensive bridging radiotherapy to extramedullary disease sites before CAR T therapy may improve PFS outcomes in multiple myeloma.
Bridging Radiotherapy Prior to CAR T May Be Safe in R/R Multiple Myeloma

October 13th 2025

The most common any-grade AE was diarrhea, occurring in 74.0% of the experimental group and 72.2% of the standard group.
Antiemetic Regimen Limits Chemo-Induced Nausea/Vomiting in Multiple Myeloma

October 6th 2025

In the analysis comparing D-VRd with other regimens for MRD-negative CR rate, there was an 81% probability that it was favorable vs Isa-VRd.
Which Therapy Has the Best Efficacy in Transplant-Ineligible NDMM?

October 1st 2025

Video Series
Video Interviews
Podcasts
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.
Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
Krina Patel, MD, MSc, discusses research and initiatives that may help to mitigate disparities in patients with multiple myeloma including factors such as gender, race, and ethnicity.
Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.
Latest CME Events & Activities

More News